STOK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 14:24):

Stats
Today's Volume	640 881
Average Volume	1.22M
Market Cap	637.87M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $-0.600 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.15
ATR14	$0.0200 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-17	Skorpios Trust	Sell	3 600 000	Common Stock
2024-04-01	Ticho Barry	Sell	442	Stock Option (Right to Buy)
2024-04-01	Ticho Barry	Buy	442	Common Stock
2024-04-01	Ticho Barry	Sell	9 426	Common Stock
2024-04-01	Nash Huw M.	Sell	50 000	Stock Option (Right to Buy)

INSIDER POWER
-65.50
Last 99 transactions
Buy: 2 052 338 \| Sell: 5 167 636

Volume Correlation

Long: 0.14 (neutral)

Short: -0.57 (weak negative)

Signal:(49.042) Neutral

Stoke Therapeutics Inc Correlation

10 Most Positive Correlations
RMRM	0.897
KINS	0.882
NXTC	0.865
NRBO	0.861
AGLE	0.858
TLGT	0.857
SVOK	0.857
BRQS	0.853
AVCT	0.853
PAIC	0.853

10 Most Negative Correlations
NRIM	-0.926
AMRB	-0.896
UFPT	-0.888
NETE	-0.887
VCYT	-0.886
MMAC	-0.885
PSL	-0.882
MMSI	-0.88
PODD	-0.879
SFM	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Stoke Therapeutics Inc Correlation - Currency/Commodity

0.88
( strong )

0.87
( strong )

0.00
( neutral )

0.39
( neutral )

0.31
( neutral )

-0.57
( weak negative )

Stoke Therapeutics Inc Financials

Annual	2023
Revenue:	$8.78M
Gross Profit:	$4.05M (46.14 %)
EPS:	$-2.38

FY	2023
Revenue:	$8.78M
Gross Profit:	$4.05M (46.14 %)
EPS:	$-2.38

FY	2022
Revenue:	$12.41M
Gross Profit:	$8.87M (71.50 %)
EPS:	$-2.39

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.33

Financial Reports:

No articles found.

Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.